A cell surface receptor called Programmed Death-1 (PD-1) serves as a T cell checkpoint and is crucial in controlling T cell exhaustion. PDL-1 or PDL-2 engagement with PD-1 causes it to become active. When the PD-1 receptor binds to its ligands, PD-L1 and PD-L2, which are expressed on cancer cells and antigen-presenting cells, it sends inhibitory checkpoint signals to activated T cells. This suppresses T-cell effector function and allows tumor immune evasion. An appealing approach for tumor immunotherapy is to block the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway.
Activated T cells, B cells, monocytes, dendritic cells, regulatory T cells, and natural killer T cells all express PD-1. It belongs to a group of immunoglobulin domain (Ig) co-receptors that affect how the T cell receptor responds when activated by an antigen-presenting cell (APC) or an infected target cell. In contrast to PD-L2, which is only and inducibly expressed on professional APCs, PD-L1 is widely expressed and constitutively on both hematopoietic and nonhematopoietic cells, including naive T and B cells, vascular endothelial cells, and pancreatic islet cells.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V75222 | Pidilizumab (CT-011; MDV9300) | 1036730-42-3 | Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody (mAb). |
|
V75221 | Pimivalimab (JTX-4014) | 2293951-22-9 | Pimivalimab (JTX-4014) is a PD-1 inhibitor. |
|
V75218 | Prolgolimab (BCD-100) | 2093956-19-3 | Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody (mAb) containing the Fc-silencing “LALA” mutation. |
|
V74271 | Reozalimab | 2445259-99-2 | Reozalimab is a bispecific antibody targeting PD-1/PD-L1. |
|
V75206 | Retifanlimab | 2079108-44-2 | Retifanlimab (Zynyz) is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). |
|
V75197 | Rosnilimab (ANB030) | 2412764-40-8 | Rosnilimab is a humanized IgG1-κ antibody directed against PD-1. |
|
V75228 | Rulonilimab | 2417124-95-7 | Rulonilimab is a human IgG1 monoclonal antibody (mAb) against PD-1 that can target, bind and inhibit PD-1 and its downstream signaling pathways, and has potential immune checkpoint inhibition and anti-tumor activity. |
|
V75227 | Sasanlimab (PF-06801591) | 2206792-50-7 | Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. |
|
V75204 | Serpulimab (HLX 10) | 2231029-82-4 | Serplulimab (HLX 10) is a humanized monoclonal anti-PD-1 antibody. |
|
V75226 | Socazolimab (ZKAB001; STI-1014; STI-A1014) | 2305043-30-3 | Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody (mAb). |
|
V1972 | Sulfamethoxypyridazine (CL13494) | 80-35-3 | Sulfamethoxypyridazine (alsoknown as CL13494)is a long-acting sulfonamide antibiotic for the treatment of dermatitis herpetiformis. |
|
V75212 | Tagitanlimab (HBM-9167; KL-A167) | 2417649-97-7 | Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). |
|
V75202 | TPP-1 | 2426685-25-6 | TPP-1 is a potent inhibitor of PD-1/PD-L1 interaction. |
|
V74876 | Tuvonralimab (PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105) | 2417649-44-4 | Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blocker consisting of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, iparomlimab and Tuvonralimab. |
|
V75196 | Visugromab (CTL-002) | 2556646-63-8 | Visugromab is a neutralizing IgG4 monoclonal antibody (mAb) against GDF-15. |
|
V74871 | Vudalimab | 2329669-72-7 | Vudalimab is a potent dual (bifunctional) inhibitor of PD-1 and CTLA-4 and a fully humanized bispecific monoclonal antibody (mAb). |
|
V75220 | Zeluvalimab (AMG-404) | 2315361-37-4 | Zeluvalimab (AMG-404) is a monoclonal antibody (mAb) targeting the PD-1 receptor and may be utilized in cancer-related research. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
